Fulcrum Therapeutics (NASDAQ:FULC) Full Year 2023 Results Key Financial Results Net loss: US$97.3m (loss narrowed by 11% from FY 2022). US$1.59 loss per share (improved from US$2.44 loss in FY 2022)....
Source LinkFulcrum Therapeutics (NASDAQ:FULC) Full Year 2023 Results Key Financial Results Net loss: US$97.3m (loss narrowed by 11% from FY 2022). US$1.59 loss per share (improved from US$2.44 loss in FY 2022)....
Source Link
Comments